Husam Alathari, MD
Psychiatry · Falls Church, VANPI 1477574549
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Alkermes, Inc. at 47.1% of the total. Reporting peaked in 2019 at $21,785 and has fallen 95.7% since, to $938 in 2025. Among psychiatry clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 241 payments — averaging $197.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$22K
- AbbVie$20K
- Indivior Inc.$2K
- Neuronetics, Inc.$961
- Otsuka America Pharmaceutical, Inc.$413
- Johnson & Johnson$352
- plus $2K from 21 others
What the payments were for
- Consulting fees$11,88025%
- Speaking & faculty fees$27,05057%
- Travel & lodging$3,0386%
- Food & beverage$5,45311%
- Education$1100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 25 | $22,388 |
| AbbVie(2 entities) | 91 | $19,986 |
| Indivior Inc. | 9 | $1,638 |
| Neuronetics, Inc. | 4 | $961 |
| Otsuka America Pharmaceutical, Inc. | 20 | $413 |
| Johnson & Johnson | 15 | $352 |
| Sunovion Pharmaceuticals Inc. | 7 | $236 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $207 |
| Vanda Pharmaceuticals Inc. | 8 | $182 |
| Lundbeck LLC | 8 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $134 |
| Supernus Pharmaceuticals, Inc. | 7 | $133 |
| Tris Pharma Inc | 1 | $124 |
| Axsome Therapeutics, Inc. | 4 | $122 |
| Teva Pharmaceuticals USA, Inc. | 4 | $84 |
| Corium, LLC | 3 | $69 |
| Neurocrine Biosciences, Inc. | 3 | $56 |
| Bausch Health US, LLC | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 2 | $51 |
| MDD US Operations, LLC | 1 | $34 |
| Shire North American Group Inc | 2 | $31 |
| Adlon Therapeutics L.p. | 2 | $30 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$51,922
- VRAYLAR$18,730
- ARISTADA INITIO$12,981
- VIVITROL$8,924
- SUBLOCADE$1,500
- NEUROSTAR TMS THERAPY SYSTEM$902
- LATUDA$125
- Quillichew ER$124
- Quillivant$124
- Dyanavel XR$124
How this compares
$47,531 in reported general payments places this provider in the 95th percentile of 884 psychiatry providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 22 | $38,090 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 191 | $36,555 |
| EmsamSelegiline | 12 | $29,230 |
| VyvanseLisdexamfetamine Dimesylate | 19 | $10,279 |
| Aripiprazole | 51 | $5,514 |
| Olanzapine | 99 | $3,361 |
| Clozapine | 41 | $2,870 |
| Duloxetine Hcl | 97 | $2,741 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 25 | $2,370 |
| Quetiapine Fumarate | 157 | $2,340 |
| Bupropion XlBupropion Hcl | 86 | $2,303 |
| Ziprasidone Hcl | 19 | $2,039 |
| Oxcarbazepine | 26 | $1,492 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 31 | $1,486 |
| Lamotrigine | 74 | $1,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $19,986 | $38,09022 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $21 | $36,555191 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $134 | $10,27919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Falls Church
- Niku SinghFalls Church$2.5M
- Michael ClarkFalls Church$18K
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
- Jasdeep MiglaniManassas$958K
- David SpiegelNorfolk$565K
- William YetterVirginia Beach$312K
- Anita ClaytonCharlottesville$260K
- Robert GardellaStaunton$201K
- Timothy KaneStaunton$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.